BioXcel Therapeutics (BTAI) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. FIS
7. ANET
8. CVS
9. SWKS
10. SPY

Go back to BioXcel Therapeutics (BTAI) Tops Q3 EPS by 8c

BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

November 14, 2019 7:00 AM EST

Key data readouts expected for BXCL501 in 1H 2020including results of pivotal Phase 3 trialswith cash position sufficient through completion of studies

Phase 1b/2 trial for geriatric dementia/Alzheimers patients on track to readout in 1H 2020

Safety data readouts expected for BXCL701 Phase 1b/2 trial in treatment emergent Neuroendocrine Prostate Cancer (tNEPC) in Q4 2019; efficacy data readouts expected in 1H 2020

NEW HAVEN, Conn.--(BUSINESS WIRE)-- BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence... More